AI Article Synopsis
- Parapneumonic pleural effusion (PPE) is a frequent issue in pneumonia patients, making prompt and precise diagnosis essential for effective treatment.
- Biomarkers in blood and pleural fluid offer easy, quick, objective, and cost-effective options for diagnosing and managing PPE.
- Despite many biomarkers being identified, none currently provide sufficient reliability for diagnosing PPE, indicating a need for future research to discover and validate more effective markers.
Article Abstract
Parapneumonic pleural effusion (PPE) is a common complication in patients with pneumonia. Timely and accurate diagnosis of PPE is of great value for its management. Measurement of biomarkers in circulating and pleural fluid have the advantages of easy accessibility, short turn-around time, objectiveness and low cost and thus have utility for PPE diagnosis and stratification. To date, many biomarkers have been reported to be of value for the management of PPE. Here, we review the values of pleural fluid and circulating biomarkers for the diagnosis and stratification PPE. The biomarkers discussed are C-reactive protein, procalcitonin, presepsin, soluble triggering receptor expressed on myeloid cells 1, lipopolysaccharide-binding protein, inflammatory markers, serum amyloid A, soluble urokinase plasminogen activator receptor, matrix metalloproteinases, pentraxin-3 and cell-free DNA. We found that none of the available biomarkers has adequate performance for diagnosing and stratifying PPE. Therefore, further work is needed to identify and validate novel biomarkers, and their combinations, for the management of PPE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10408363.2022.2158779 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of polymerase chain reaction to characterize the etiology of culture-negative empyema and parapneumonic effusion among Alaska Native children - 2018-2023.
J Pediatric Infect Dis Soc
December 2024
Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, U.S.A.
We used polymerase chain reaction (PCR) to identify bacterial infections in culture-negative pleural fluid specimens from Alaska Native children hospitalized with empyema. PCR identified ≥1 organism in 11 (79%) of 14 specimens. Streptococcus pneumoniae serotype 3 was detected in six specimens; all six participants had received 13-valent pneumococcal conjugate vaccine.
View Article and Find Full Text PDFDiagnostic accuracy of cancer ratio and other new parameters in differentiating malignant from benign pleural effusions.
Monaldi Arch Chest Dis
December 2024
Department of Pulmonary Medicine, Nizam's Institute of Medical Sciences, Hyderabad.
Differentiation of malignant from benign pleural effusions is challenging in clinical practice due to limitations in the cytologic analysis. The combination of pleural fluid biomarkers has previously been used to predict malignant pleural effusion (MPE). We have conducted a prospective observational study to assess the diagnostic potential of cancer ratio [(CR) serum lactate dehydrogenase (sLDH): pleural fluid adenosine deaminase (pADA)], CR plus (CR: pleural lymphocyte count), sLDH: pleural lymphocyte count, and age: pADA in differentiating malignant effusions from benign ones.
View Article and Find Full Text PDFGranzyme A as biomarker for diagnosis in tuberculous pleural effusion.
JCI Insight
December 2024
Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Department of Pathogen Biology, Shenzhen University Medical School, Shenzhen, China.
BACKGROUNDCurrent diagnostic tools for tuberculous pleural effusion (TPE) are often inadequate, making accurate diagnosis challenging. Effective identification of TPE is critical for ensuring proper treatment and preventing tuberculosis relapse. This study explored the potential of granzyme A (GZMA) as a biomarker for TPE.
View Article and Find Full Text PDFBeyond diagnosis: maximizing the role of medical thoracoscopy in pleural disease treatment.
Respir Res
November 2024
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- * It helps with thoracic drainage, which can shorten hospital stays for patients with complicated effusions and empyema, and can be used for treating pneumothorax and other conditions.
- * Despite its potential, there are no standardized protocols for certain treatments, and more quality clinical research is needed to fully confirm its effectiveness in various applications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!